


## Niraparib tosylate

<b>Cat. No.:</b>	HY-10619B
<b>CAS No.:</b>	1038915-73-9
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>28</sub> N <sub>4</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	492.59
<b>Target:</b>	PARP; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (203.01 mM; ultrasonic and warming and heat to 60°C)					
	H <sub>2</sub> O : 1 mg/mL (2.03 mM; heat to 50°C)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.0301 mL	10.1504 mL	20.3009 mL
<b>5 mM</b>			0.4060 mL	2.0301 mL	4.0602 mL	
	<b>10 mM</b>		0.2030 mL	1.0150 mL	2.0301 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution					
	2. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution					
	3. Add each solvent one by one: 1% DMSO >> 99% saline Solubility: ≥ 0.5 mg/mL (1.02 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC <sub>50</sub> of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity <sup>[1][2][3]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	PARP-2 2.1 nM (IC <sub>50</sub> )	PARP-1 3.8 nM (IC <sub>50</sub> )	V-PARP 330 nM (IC <sub>50</sub> )	TANK-1 570 nM (IC <sub>50</sub> )
	PARP-3			

	1300 nM (IC <sub>50</sub> )
<b>In Vitro</b>	<p>Niraparib (MK-4827) inhibits PARP activity with EC<sub>50</sub>=4 nM and EC<sub>90</sub>=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC<sub>50</sub> in the 10–100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC<sub>50</sub>=3.8 and 2.1 nM, respectively, and in a whole cell assay<sup>[1]</sup>. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM Niraparib (MK-4827) for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vd<sub>ss</sub>=6.9 L/kg), long terminal half-life (t<sub>1/2</sub>=3.4 h), and excellent bioavailability, F=65%<sup>[1]</sup>. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## PROTOCOL

<b>Cell Assay</b> <sup>[2]</sup>	<p>The inhibition of PARP is analyzed in A549 and H1299 cells using the HT Universal Chemiluminescent PARP Assay Kit. Briefly, cells are treated with DMSO or 1 μM Niraparib (MK-4827) for 15, 30, 60, or 120 minutes, trypsinized, and transferred to a pre-chilled tube. The cells are washed twice with ice cold PBS and resuspended in cold PARP extraction buffer. The cell suspensions are incubated on ice for 30 minutes with periodic vortexing to disrupt the cell membrane. The suspensions are centrifuged and the supernatant transferred to a pre-chilled tube on ice. The histone coated wells of the 96-well plate are rehydrated with 1X PARP buffer and incubated at room temperature for 30 minutes. The PARP buffer is removed and 20 μg of protein as determined by the Bio-Rad Protein Assay is added to each well followed by diluted PARP-HSA enzyme and 1X PARP buffer. The strip wells are then incubated at room temperature for 60 minutes, washed twice with PBS containing 0.1% Triton X-100, and then washed with PBS. Diluted Strep-HRP is added to the strip wells and incubated for 60 minutes at room temperature. The wells are washed again as before. Equal volumes of PeroxyGlow A and B are combined and added to the wells and chemiluminescent readings are obtained immediately using a plate-reader<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>Animal Administration</b> <sup>[3]</sup>	<p>Mice<sup>[3]</sup></p> <p>Female nude mice (Ncr Nu/Nu) are randomly assigned to treatment groups consisting of 5 to 8 mice each when tumors grew to 6.0 mm in diameter at which time treatment with MK-4827 is initiated. MK-4827 is given at a dose of 25 mg/kg twice daily or 50 mg/kg once daily for either 21 days or is discontinued at 9 days from the time tumors reached 8 mm in diameter. Fractionated local tumor irradiation (XRT) is given when tumors reach 8.0 mm in diameter (7.7-8.2 mm). Radiation (2 Gy per fraction) is delivered to the tumor-bearing leg of mice once daily for 14 consecutive days or twice daily for 7 consecutive days using a small-animal irradiator consisting of two parallel-opposed <sup>137</sup>Cs sources, at a dose rate of 5 Gy/min. During irradiation un-anesthetized mice are mechanically immobilized in a jig so that the tumor is centered within a 3.0 cm diameter radiation field and the animal's body shielded from radiation exposure. On the day when both MK-4827 and radiation are given, drug is administered 1 h before the first radiation dose of the day.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## CUSTOMER VALIDATION

- Cancer Discov. 2017 Sep;7(9):984-998.

- Cancer Cell. 2020 Dec 14;38(6):844-856.e7.
- J Clin Invest. 2019 Mar 1;129(3):1211-1228.
- Clin Cancer Res. 2017 Feb 15;23(4):1001-1011.
- Cancer Res. 2022 Apr 26;canres.CAN-22-0742-E.2022.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Jones P, et al. Discovery of 2-[4-[(3S)-piperidin-3-yl]phenyl]-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
- [2]. Bridges KA, et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5(13):5076-86.
- [3]. Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20.
- [4]. Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA